Core Viewpoint - The company, Nuo Cheng Jian Hua, reported significant growth in Q1 2025, with a revenue increase of 129.92% year-on-year, driven primarily by the sales of its core product, Acalabrutinib (brand name: Ibrutinib) [1][4][5]. Financial Performance - Q1 2025 revenue reached 381 million yuan, up from 165.82 million yuan in the same period last year, marking a 129.92% increase [3]. - The net profit attributable to shareholders was 17.97 million yuan, a turnaround from a loss of 142.4 million yuan in the previous year [3]. - Gross margin improved to 90.5%, an increase of 5.1 percentage points year-on-year [1][3]. Product Performance - Acalabrutinib sales reached 311.67 million yuan in Q1 2025, reflecting a year-on-year growth of 89.22% [5]. - The product has received approval for its first-line treatment indication for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in adults, expected to enter medical insurance this year, which is anticipated to be a new growth driver for the company [4][6][7]. Research and Development - The company invested approximately 207.6 million yuan in R&D, which accounted for 54.45% of its revenue, a decrease of 52.73 percentage points compared to the previous year [3]. - Nuo Cheng Jian Hua aims to develop five to six innovative drugs over the next three to five years, with ongoing clinical trials for various indications [8][9]. Strategic Partnerships - The company signed a strategic cooperation framework agreement with Westlake University to enhance drug development and talent cultivation, with funding support not exceeding 54 million yuan [9]. - Nuo Cheng Jian Hua is actively exploring international collaborations and licensing agreements to expand its business beyond the Chinese market [9]. Financial Position - As of March 31, 2025, the company had cash and cash equivalents totaling approximately 4.84 billion yuan, with total liquid assets around 7.78 billion yuan [10].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [5]. Core Insights - The recent positive results from Eli Lilly's oral GLP-1 small molecule Orforglipron in Phase 3 clinical trials (ACHIEVE-1) are significant for diabetes treatment, potentially increasing the number of oral medications available before insulin use [2][15]. - The global market for GLP-1 drugs is substantial, with projected sales of approximately $51.8 billion in 2024, of which $37.71 billion (73%) is for diabetes products and $14.06 billion (27%) for obesity products, indicating strong future growth potential for oral GLP-1 small molecules [20][21]. Summary by Sections Weekly New Drug Market Review - From April 14 to April 20, 2025, the top five companies in the new drug sector by stock price increase were: Boan Biotechnology (68.01%), Fuhong Hanlin (18.71%), Junsheng Tai (16.20%), Nothland (11.00%), and Yifang Biotechnology (10.48%). The top five companies with stock price declines were: Youzhiyou (-21.19%), Beihai Kangcheng (-16.57%), Aidi Pharmaceutical (-9.48%), Geely Pharmaceutical (-7.84%), and Haishike (-7.54%) [1][11]. Key Analysis of the New Drug Industry - Eli Lilly's Orforglipron demonstrated a significant reduction in HbA1c levels, with an average decrease from a baseline of 8.0% to between 1.3% and 1.6%. Over 65% of patients achieved an A1C level of ≤6.5%, and patients lost an average of 7.9% of their body weight during the trial [15][16]. New Drug Approvals and Applications - This week, three new drugs or new indications were approved for market entry in China, with 299 new drug INDs approved and 38 new drug INDs accepted for review [3][24]. Domestic New Drug Industry Highlights - On April 18, 2025, Kangfang Biologics' monoclonal antibody injection for IL-12/IL-23 received NMPA approval for psoriasis treatment [4]. - On April 17, 2025, BeiGene's new BCL2 inhibitor was prioritized for review for chronic lymphocytic leukemia and small lymphocytic lymphoma [4]. Overseas New Drug Industry Highlights - Eli Lilly's Orforglipron Phase 3 trial results were announced on April 18, 2025 [7]. - On April 16, 2025, Eisai and Biogen's Leqembi for Alzheimer's disease received EU approval [7]. - On April 14, 2025, Bristol-Myers Squibb's PD-1 inhibitor was approved by the FDA for liver cancer treatment [7].